Evaluation of serum mesothelin in malignant and benign ovarian masses
Purpose To evaluate the diagnostic accuracy of serum mesothelin levels in patients with ovarian masses in comparison to serum cancer antigen (CA) 125 levels. Methods This diagnostic accuracy study was conducted in a gynecological oncology unit at Ain Shams University Maternity hospital. Based on rad...
Gespeichert in:
| Veröffentlicht in: | Archives of gynecology and obstetrics 2014-07, Vol.290 (1), p.107-113 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113 |
|---|---|
| container_issue | 1 |
| container_start_page | 107 |
| container_title | Archives of gynecology and obstetrics |
| container_volume | 290 |
| creator | Ibrahim, Moustafa Bahaa, Ahmed Ibrahim, Ahmed El Hakem, Amira Abd Abo-El Noor, Ayman El Tohamy, Usama |
| description | Purpose
To evaluate the diagnostic accuracy of serum mesothelin levels in patients with ovarian masses in comparison to serum cancer antigen (CA) 125 levels.
Methods
This diagnostic accuracy study was conducted in a gynecological oncology unit at Ain Shams University Maternity hospital. Based on radiological and clinical findings, a total of 110 patients were consecutively recruited. Preoperative serum mesothelin levels were assessed using enzyme-linked immunosorbent assay (ELISA) technique, while CA125 levels were determined using electrochemiluminescence immunoassay. All patients underwent exploratory laparotomy. Preoperative serum levels of both markers were correlated to histopathological reports obtained from each patient.
Results
A total of 96 patients were finally analyzed. Of the included 96 patients, 58 (60.4 %) had a benign ovarian lesion, while 38 (39.6 %) had a malignant lesion. The median serum CA125 levels were significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [335.5 mIU/mL (range 60–1,127 mIU/mL) versus 33.65 mIU/mL (range 10.36–174 mIU/mL),
P
|
| doi_str_mv | 10.1007/s00404-014-3147-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1535623488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2261876473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-f859495bb3af209295fe41c506c7a5d0363ef937b47557940971889dcddaf4f13</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMo7vrxA7xIwYuX6iSZNM1RlvUDFrzoOaRtol3aVJNW8N-bZVcFQQhMwjzzZngIOaNwRQHkdQRAwBwo5pyizNkemVPkLAdJ6T6Zg9rcoZAzchTjGoCysiwOyYwholAFzsly-WG6yYzt4LPBZdGGqc96G4fx1Xatz9LpTde-eOPHzPgmq6xPr2z4MKE1m2aMNp6QA2e6aE939Zg83y6fFvf56vHuYXGzymtENuauFAqVqCpuHAPFlHAWaS2gqKURDfCCW6e4rFAKIRWCkrQsVVM3jXHoKD8ml9vctzC8TzaOum9jbbvOeDtMUVPBRcE4lmVCL_6g62EKPm2nGStoKQuUPFF0S9VhiDFYp99C25vwqSnojWO9dayTY71xrFmaOd8lT1Vvm5-Jb6kJYFsgppZ_seH36_9TvwBUd4Uf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2261876473</pqid></control><display><type>article</type><title>Evaluation of serum mesothelin in malignant and benign ovarian masses</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ibrahim, Moustafa ; Bahaa, Ahmed ; Ibrahim, Ahmed ; El Hakem, Amira Abd ; Abo-El Noor, Ayman ; El Tohamy, Usama</creator><creatorcontrib>Ibrahim, Moustafa ; Bahaa, Ahmed ; Ibrahim, Ahmed ; El Hakem, Amira Abd ; Abo-El Noor, Ayman ; El Tohamy, Usama</creatorcontrib><description>Purpose
To evaluate the diagnostic accuracy of serum mesothelin levels in patients with ovarian masses in comparison to serum cancer antigen (CA) 125 levels.
Methods
This diagnostic accuracy study was conducted in a gynecological oncology unit at Ain Shams University Maternity hospital. Based on radiological and clinical findings, a total of 110 patients were consecutively recruited. Preoperative serum mesothelin levels were assessed using enzyme-linked immunosorbent assay (ELISA) technique, while CA125 levels were determined using electrochemiluminescence immunoassay. All patients underwent exploratory laparotomy. Preoperative serum levels of both markers were correlated to histopathological reports obtained from each patient.
Results
A total of 96 patients were finally analyzed. Of the included 96 patients, 58 (60.4 %) had a benign ovarian lesion, while 38 (39.6 %) had a malignant lesion. The median serum CA125 levels were significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [335.5 mIU/mL (range 60–1,127 mIU/mL) versus 33.65 mIU/mL (range 10.36–174 mIU/mL),
P
< 0.001]. The median serum mesothelin level was significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [104.1 nmol/L (range 6.5–215.4 nmol/L) versus 12.65 nmol/L (range 6.5–102 nmol/L),
P
< 0.001]. The diagnostic sensitivity and specificity for mesothelin and CA125 were 97.4 and 98.3 % and 97.4 and 56.9 %, respectively. The combination of mesothelin with CA125 did not add predictive value to mesothelin compared with mesothelin alone [same sensitivity (97.4 %) and same specificity (98.3 %)]. Serum mesothelin levels rather than serum CA125 levels were a significant predictor of early-stage ovarian malignancy [Area under the curve = 0.732, 95 % confidence interval (0.543–0.921),
P
= 0.031].
Conclusion
In ovarian cancer, mesothelin seemed to have the same sensitivity, but a higher specificity than CA125. Combination of mesothelin and CA125 had no advantage over mesothelin alone. Mesothelin rather than CA125 was a significant predictor of early-stage ovarian cancer (stage I/II).</description><identifier>ISSN: 0932-0067</identifier><identifier>EISSN: 1432-0711</identifier><identifier>DOI: 10.1007/s00404-014-3147-2</identifier><identifier>PMID: 24445964</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; Endocrinology ; Enzyme-Linked Immunosorbent Assay ; Female ; GPI-Linked Proteins - blood ; Gynecologic Oncology ; Gynecology ; Human Genetics ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Obstetrics/Perinatology/Midwifery ; Ovarian cancer ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - pathology ; Sensitivity and Specificity ; Young Adult</subject><ispartof>Archives of gynecology and obstetrics, 2014-07, Vol.290 (1), p.107-113</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Archives of Gynecology and Obstetrics is a copyright of Springer, (2014). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-f859495bb3af209295fe41c506c7a5d0363ef937b47557940971889dcddaf4f13</citedby><cites>FETCH-LOGICAL-c442t-f859495bb3af209295fe41c506c7a5d0363ef937b47557940971889dcddaf4f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00404-014-3147-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00404-014-3147-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24445964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ibrahim, Moustafa</creatorcontrib><creatorcontrib>Bahaa, Ahmed</creatorcontrib><creatorcontrib>Ibrahim, Ahmed</creatorcontrib><creatorcontrib>El Hakem, Amira Abd</creatorcontrib><creatorcontrib>Abo-El Noor, Ayman</creatorcontrib><creatorcontrib>El Tohamy, Usama</creatorcontrib><title>Evaluation of serum mesothelin in malignant and benign ovarian masses</title><title>Archives of gynecology and obstetrics</title><addtitle>Arch Gynecol Obstet</addtitle><addtitle>Arch Gynecol Obstet</addtitle><description>Purpose
To evaluate the diagnostic accuracy of serum mesothelin levels in patients with ovarian masses in comparison to serum cancer antigen (CA) 125 levels.
Methods
This diagnostic accuracy study was conducted in a gynecological oncology unit at Ain Shams University Maternity hospital. Based on radiological and clinical findings, a total of 110 patients were consecutively recruited. Preoperative serum mesothelin levels were assessed using enzyme-linked immunosorbent assay (ELISA) technique, while CA125 levels were determined using electrochemiluminescence immunoassay. All patients underwent exploratory laparotomy. Preoperative serum levels of both markers were correlated to histopathological reports obtained from each patient.
Results
A total of 96 patients were finally analyzed. Of the included 96 patients, 58 (60.4 %) had a benign ovarian lesion, while 38 (39.6 %) had a malignant lesion. The median serum CA125 levels were significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [335.5 mIU/mL (range 60–1,127 mIU/mL) versus 33.65 mIU/mL (range 10.36–174 mIU/mL),
P
< 0.001]. The median serum mesothelin level was significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [104.1 nmol/L (range 6.5–215.4 nmol/L) versus 12.65 nmol/L (range 6.5–102 nmol/L),
P
< 0.001]. The diagnostic sensitivity and specificity for mesothelin and CA125 were 97.4 and 98.3 % and 97.4 and 56.9 %, respectively. The combination of mesothelin with CA125 did not add predictive value to mesothelin compared with mesothelin alone [same sensitivity (97.4 %) and same specificity (98.3 %)]. Serum mesothelin levels rather than serum CA125 levels were a significant predictor of early-stage ovarian malignancy [Area under the curve = 0.732, 95 % confidence interval (0.543–0.921),
P
= 0.031].
Conclusion
In ovarian cancer, mesothelin seemed to have the same sensitivity, but a higher specificity than CA125. Combination of mesothelin and CA125 had no advantage over mesothelin alone. Mesothelin rather than CA125 was a significant predictor of early-stage ovarian cancer (stage I/II).</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>Endocrinology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>GPI-Linked Proteins - blood</subject><subject>Gynecologic Oncology</subject><subject>Gynecology</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Obstetrics/Perinatology/Midwifery</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Sensitivity and Specificity</subject><subject>Young Adult</subject><issn>0932-0067</issn><issn>1432-0711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LxDAQhoMo7vrxA7xIwYuX6iSZNM1RlvUDFrzoOaRtol3aVJNW8N-bZVcFQQhMwjzzZngIOaNwRQHkdQRAwBwo5pyizNkemVPkLAdJ6T6Zg9rcoZAzchTjGoCysiwOyYwholAFzsly-WG6yYzt4LPBZdGGqc96G4fx1Xatz9LpTde-eOPHzPgmq6xPr2z4MKE1m2aMNp6QA2e6aE939Zg83y6fFvf56vHuYXGzymtENuauFAqVqCpuHAPFlHAWaS2gqKURDfCCW6e4rFAKIRWCkrQsVVM3jXHoKD8ml9vctzC8TzaOum9jbbvOeDtMUVPBRcE4lmVCL_6g62EKPm2nGStoKQuUPFF0S9VhiDFYp99C25vwqSnojWO9dayTY71xrFmaOd8lT1Vvm5-Jb6kJYFsgppZ_seH36_9TvwBUd4Uf</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Ibrahim, Moustafa</creator><creator>Bahaa, Ahmed</creator><creator>Ibrahim, Ahmed</creator><creator>El Hakem, Amira Abd</creator><creator>Abo-El Noor, Ayman</creator><creator>El Tohamy, Usama</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140701</creationdate><title>Evaluation of serum mesothelin in malignant and benign ovarian masses</title><author>Ibrahim, Moustafa ; Bahaa, Ahmed ; Ibrahim, Ahmed ; El Hakem, Amira Abd ; Abo-El Noor, Ayman ; El Tohamy, Usama</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-f859495bb3af209295fe41c506c7a5d0363ef937b47557940971889dcddaf4f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>Endocrinology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>GPI-Linked Proteins - blood</topic><topic>Gynecologic Oncology</topic><topic>Gynecology</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Obstetrics/Perinatology/Midwifery</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Sensitivity and Specificity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ibrahim, Moustafa</creatorcontrib><creatorcontrib>Bahaa, Ahmed</creatorcontrib><creatorcontrib>Ibrahim, Ahmed</creatorcontrib><creatorcontrib>El Hakem, Amira Abd</creatorcontrib><creatorcontrib>Abo-El Noor, Ayman</creatorcontrib><creatorcontrib>El Tohamy, Usama</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ibrahim, Moustafa</au><au>Bahaa, Ahmed</au><au>Ibrahim, Ahmed</au><au>El Hakem, Amira Abd</au><au>Abo-El Noor, Ayman</au><au>El Tohamy, Usama</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of serum mesothelin in malignant and benign ovarian masses</atitle><jtitle>Archives of gynecology and obstetrics</jtitle><stitle>Arch Gynecol Obstet</stitle><addtitle>Arch Gynecol Obstet</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>290</volume><issue>1</issue><spage>107</spage><epage>113</epage><pages>107-113</pages><issn>0932-0067</issn><eissn>1432-0711</eissn><abstract>Purpose
To evaluate the diagnostic accuracy of serum mesothelin levels in patients with ovarian masses in comparison to serum cancer antigen (CA) 125 levels.
Methods
This diagnostic accuracy study was conducted in a gynecological oncology unit at Ain Shams University Maternity hospital. Based on radiological and clinical findings, a total of 110 patients were consecutively recruited. Preoperative serum mesothelin levels were assessed using enzyme-linked immunosorbent assay (ELISA) technique, while CA125 levels were determined using electrochemiluminescence immunoassay. All patients underwent exploratory laparotomy. Preoperative serum levels of both markers were correlated to histopathological reports obtained from each patient.
Results
A total of 96 patients were finally analyzed. Of the included 96 patients, 58 (60.4 %) had a benign ovarian lesion, while 38 (39.6 %) had a malignant lesion. The median serum CA125 levels were significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [335.5 mIU/mL (range 60–1,127 mIU/mL) versus 33.65 mIU/mL (range 10.36–174 mIU/mL),
P
< 0.001]. The median serum mesothelin level was significantly higher in patients with malignant ovarian lesions than in patients with benign ovarian lesions [104.1 nmol/L (range 6.5–215.4 nmol/L) versus 12.65 nmol/L (range 6.5–102 nmol/L),
P
< 0.001]. The diagnostic sensitivity and specificity for mesothelin and CA125 were 97.4 and 98.3 % and 97.4 and 56.9 %, respectively. The combination of mesothelin with CA125 did not add predictive value to mesothelin compared with mesothelin alone [same sensitivity (97.4 %) and same specificity (98.3 %)]. Serum mesothelin levels rather than serum CA125 levels were a significant predictor of early-stage ovarian malignancy [Area under the curve = 0.732, 95 % confidence interval (0.543–0.921),
P
= 0.031].
Conclusion
In ovarian cancer, mesothelin seemed to have the same sensitivity, but a higher specificity than CA125. Combination of mesothelin and CA125 had no advantage over mesothelin alone. Mesothelin rather than CA125 was a significant predictor of early-stage ovarian cancer (stage I/II).</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>24445964</pmid><doi>10.1007/s00404-014-3147-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0932-0067 |
| ispartof | Archives of gynecology and obstetrics, 2014-07, Vol.290 (1), p.107-113 |
| issn | 0932-0067 1432-0711 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1535623488 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Biomarkers, Tumor - blood CA-125 Antigen - blood Endocrinology Enzyme-Linked Immunosorbent Assay Female GPI-Linked Proteins - blood Gynecologic Oncology Gynecology Human Genetics Humans Medicine Medicine & Public Health Middle Aged Obstetrics/Perinatology/Midwifery Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Sensitivity and Specificity Young Adult |
| title | Evaluation of serum mesothelin in malignant and benign ovarian masses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20serum%20mesothelin%20in%20malignant%20and%20benign%20ovarian%20masses&rft.jtitle=Archives%20of%20gynecology%20and%20obstetrics&rft.au=Ibrahim,%20Moustafa&rft.date=2014-07-01&rft.volume=290&rft.issue=1&rft.spage=107&rft.epage=113&rft.pages=107-113&rft.issn=0932-0067&rft.eissn=1432-0711&rft_id=info:doi/10.1007/s00404-014-3147-2&rft_dat=%3Cproquest_cross%3E2261876473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2261876473&rft_id=info:pmid/24445964&rfr_iscdi=true |